Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial